Rich lister’s upcoming hemp IPO eyes profitability
Industrial hemp company Ecofibre Ltd is shaping up to be the biggest name in Australia’s small but fast moving cannabis space.
The company, headed by rich-lister Barry Lambert, is gearing up to list on the ASX by the end of this month with big plans to capitalise on the opening of hemp markets in Australia and the US.
The global hemp fibre market presents serious opportunity with forecasts that it will be worth US$4.4 billion by 2025, up from US$1.7 billion last year. And while hemp still remains strictly regulated in Australia — although the consumption of hemp foods became legal in 2017 — hemp products are now mainstream in the US.
It’s a case of consumers becoming increasingly aware of hemp’s benefits, and regulators responding to make hemp products more accessible.
Lambert, along with CEO Eric Wang, who is a former CEO of $1.7 billion capped Perpetual (ASX:PPT), is seeking to raise up to $20 million at $1 a share for the IPO offering, which would value Ecofibre at more than $300 million.
What’s interesting for retail investors is that, unlike many IPOs, a portion (around 20%) of the raising will be available for the general public — the prospectus is available on Ecofibre’s website.
Wang’s background means he’s well placed to attract some serious institutional funding, and has already secured backing from IMF Investors.
Lambert isn’t without connections himself, having built Count Financial which he sold in 2011 to Commonwealth Bank for $373 million. He’s leveraging his connections with fund managers and high net worth investors who had backed Count Financial to now get behind Ecofibre.
In a strong sign of confidence, Lambert, himself, will hold 24% of the group post-IPO, while Wang will control 18%.
The company has experience in breeding and growing hemp — knowledge that’s been commercialised over the past two years with sales growing rapidly and strong margins across its businesses.
Although the company has run at an $8.7 million loss over the past two years, it is expected to break even this year, before becoming profitable from FY20.
The funds raised will be applied to expand Ecofibre’s businesses, with a strong emphasis on developing its high-tech fibre textile, Hemp Black.
Hemp Black, its industrial use business, focuses on highly innovative solutions across a spectrum of consumer markets including fashion, athleisure wear, healthcare, composites and building materials.
Wang says that this high-tech fibre textile, Hemp Black “is the future”. He explains that there is a broad application of the textile — it can be used in 3D printing, or in hospitals or office furniture as the fibre's anti-microbial properties means you're not spreading germs.
Here’s a video explaining what exactly Hemp Black is:
This business is expected to be a major future earnings driver with its innovative hemp-based products in textiles that Ecofibre is developing in partnership with Thomas Jefferson University in Philadelphia.
Ecofibre’s other businesses are Ananda Health, which produces nutraceutical products and is now at economic scale, profitable and growing rapidly, as well as Ananda Food, which is a major-scale producer of food-grade hemp seed oil, protein and hemp seeds grown from industrial hemp crops in Tasmania.
By owning the whole value chain, from seed to shelf, Ecofibre produces nutraceutical products for human and pet consumption, as well as topical creams and salves via its Ananda Health and Ananda Food brands.
Ananda Professional brings to market the first fully compliant and legal CBD oil product line created specifically for the needs of independent pharmacies and healthcare professionals. This exclusive professional line meets strict safety standards with its pharmaceutical grade full spectrum cannabinoids.
Ecofibre has its cannabis-infused products in more than 2000 US pharmacies, and hopes to lift its presence as the big chains like Walmart begin stocking these types of items this year.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.